Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thorough ECG crossover study of VX-770 in healthy adults
NL-OMON34380Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ivacaftor in cystic fibrosis (CF) (5 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Part A safety and tolerability and Part B placebo-subtracted QTcF. Started May 2010; status: active, not recruiting.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON34380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34380.